Immunotherapy – a new era for cancer treatment
Recent cancer drug trials have highlighted the clinical effectiveness of immunotherapy, where the body's immune system is used to attack cancerous cells.
The international trial of ipilimumab and nivolumab, which are used to treat advanced melanoma, were shown to shrink tumours in 58% of cases.
Here at CCL, immunotherapy has been used alongside chemotherapy for some time with good results, especially in solid tumours. Consultant Medical Oncologist Professor Angus Dalgleish will be involved in this latest development, with further drug treatments for myeloma and other haematological malignancies expected shortly.